# Concord Biotech (NSE: CONCORDBIO) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/CONCORDBIO · Pivot · prices to 22 Oct 2026

Concord Biotech (NSE: CONCORDBIO) closed at ₹1,298.00 on 22 Oct 2026, up 1.80% on the day. With a market capitalisation of ₹13,286 Cr, it ranks 476th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Biotechnology.

At its last close the stock traded at 52.4× trailing earnings. Over the past year the share price has fallen 14.6%. Its 52-week range is ₹987.00 (2 Apr 2026) to ₹1,615.00 (20 Aug 2026); the last close is 19.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹257 Cr (+26.2% year on year) and net profit ₹56 Cr (+32.5%), on a consolidated basis. Promoters held 44.08% of the company as of 30 Jun 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Last close | ₹1,298.00 |
| Market cap | ₹13,286 Cr |
| P/E (trailing) | 52.4 |
| Debt to equity | 0 |
| 52-week high | ₹1,615.00 (20 Aug 2026) |
| 52-week low | ₹987.00 (2 Apr 2026) |
| 1-year return | −14.6% |

## Quarterly results (₹ crore, consolidated)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q1 FY27 | ₹257 Cr | +26.2% | ₹56 Cr | +32.5% | ₹5.52 |
| Q4 FY26 | ₹326 Cr | −24.1% | ₹89 Cr | −37.6% | ₹8.46 |
| Q3 FY26 | ₹278 Cr | +13.7% | ₹64 Cr | −13.2% | ₹6.08 |
| Q2 FY26 | ₹247 Cr | −20.3% | ₹61 Cr | −38.4% | ₹6.03 |
| Q1 FY26 | ₹204 Cr | −5.5% | ₹43 Cr | −26.9% | ₹4.21 |
| Q4 FY25 | ₹430 Cr | +34.8% | ₹142 Cr | +46.0% | ₹13.42 |
| Q3 FY25 | ₹244 Cr | +1.4% | ₹74 Cr | −0.6% | ₹7.26 |
| Q2 FY25 | ₹310 Cr | +18.2% | ₹99 Cr | +16.8% | ₹9.15 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹1,200 Cr | ₹373 Cr |
| FY24 | ₹1,017 Cr | ₹305 Cr |

## Shareholding (30 Jun 2026)

- Promoters: 44.08%
- Foreign institutions: 7.52%
- Domestic institutions: 9.36%
- Non-institutions: 39.03%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Vijaya Diagnostic Centre](https://app.pivotnow.in/stock/VIJAYA) | ₹1,382.60 | ₹14,324 Cr | 82.5 | 18.1% |
| [Natco Pharma](https://app.pivotnow.in/stock/NATCOPHARM) | ₹785.00 | ₹14,063 Cr | 9.9 | 15.4% |
| [Indegene](https://app.pivotnow.in/stock/INDGN) | ₹577.95 | ₹13,987 Cr | 34.8 | 12.8% |
| [Marksans Pharma](https://app.pivotnow.in/stock/MARKSANS) | ₹295.80 | ₹13,343 Cr | 32.1 | 13.8% |
| [CORONA Remedies](https://app.pivotnow.in/stock/CORONA) | ₹2,024.70 | ₹12,360 Cr | 66.8 | 24.8% |
| [Rainbow Childrens Medicare](https://app.pivotnow.in/stock/RAINBOW) | ₹1,205.70 | ₹12,245 Cr | 43.9 | — |

## Questions and answers

### What is the share price of Concord Biotech today?

Concord Biotech (NSE: CONCORDBIO) last closed at ₹1,298.00 on 22 Oct 2026. Its 52-week high is ₹1,615.00 and its 52-week low is ₹987.00.

### What is the market cap of Concord Biotech?

Concord Biotech's market capitalisation is ₹13,286 Cr (₹13,286 Cr) at the 22 Oct 2026 close, ranking 476th among the NSE companies Pivot tracks.

### What is the P/E ratio of Concord Biotech?

Concord Biotech trades at a trailing P/E of 52.4. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 43.9.

### Is Concord Biotech a debt-free company?

Concord Biotech is close to debt-free: its debt-to-equity ratio was 0 in FY26.

### What were Concord Biotech's latest quarterly results?

For Q1 FY27 (quarter ended 30 Jun 2026), Concord Biotech reported revenue of ₹257 Cr, +26.2% year on year, and net profit of ₹56 Cr, +32.5% year on year.

### How has Concord Biotech stock performed over the last year?

Concord Biotech's share price has fallen 14.6% over the past year, +1.8% over three months and −17.3% over one month, to the 22 Oct 2026 close.

### What is the shareholding pattern of Concord Biotech?

As of 30 Jun 2026: promoters 44.08%, foreign institutions 7.52%, domestic institutions 9.36%, non-institutions 39.03%.

### Who are Concord Biotech's competitors?

The listed Pharma & Healthcare companies closest to Concord Biotech by market cap are Vijaya Diagnostic Centre, Natco Pharma, Indegene, Marksans Pharma, CORONA Remedies and Rainbow Childrens Medicare.

### Is Concord Biotech a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Concord Biotech's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on CONCORDBIO against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.